Nuformix Plc (NFX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

GBP 5 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.10

Return on Equity

-92.37%

Price to Book

5.19

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

160.0%

6 Months

136.36%

1 Year

333.33%

2 Years

-10.34%

3 Years

-29.73%

4 Years

-82.31%

5 Years

-90.19%

Nuformix Plc for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-14.38%

EBIT Growth (5y)

5.06%

EBIT to Interest (avg)

-1.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.10

Sales to Capital Employed (avg)

0.02

Tax Ratio

0.12%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.01

EV to EBIT

-4.91

EV to EBITDA

-4.91

EV to Capital Employed

4.91

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-64.05%

ROE (Latest)

-92.37%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Nuformix Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.60",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Sep'23

Sep'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.60

0.00

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.60

0.00

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Results

Company CV

About Nuformix Plc

Nuformix Plc

Pharmaceuticals & Biotechnology

Nuformix PLC, formerly Levrett PLC, is a United Kingdom-based pharmaceutical development company. The Company uses cocrystal technology to develop drugs with programs in oncology supportive care and fibrosis. It uses cocrystal technology to re-engineer the crystalline form of drugs. Its clinical pipeline includes NXP001 and NXP002. Its pre-clinical pipeline includes NXP003. It is developing NXP001 for oncology supportive care. It is developing NXP002 for the treatment of multiple fibrotic diseases. NXP003 targets a mechanism understood to confer resistance to immuno-oncology, chemotherapy and radiotherapy cancer treatments.

Company Coordinates

Company Details

153 Science Park, Milton Road , CAMBRIDGE None : CB4 0GN

Tel: 44 1223 627222

https://nuformix.com/

Registrar Details